Betamak T50

Betamak T50: use, dosage, side effects and contraindications

Betamak T50 is one of the drugs belonging to the group of antipsychotics - substituted benzamides. The drug contains the active substance sulpiride, which is widely used in the treatment of various mental disorders and other diseases.

The drug is available in the form of film-coated tablets containing 50 mg of sulpiride. The country of origin of Betamak T50 is Japan, and the manufacturer is Sawai Pharmaceutical Co. Ltd.

Indications for use

Betamak T50 is indicated for the treatment of schizophrenia (including sluggish forms, accompanied by lethargy and lethargy), acute and chronic psychoses, gastric and duodenal ulcers, migraines, dizziness, post-traumatic encephalopathy and behavioral disorders in children.

Dosage and method of administration

The dosage of Betamak T50 should be prescribed individually depending on the severity of the disease and other factors. It is usually recommended to start treatment with 50-100 mg of sulpiride per day, divided into 2-3 doses. Further dose adjustment should be carried out under the supervision of a physician.

Side effects

Betamak T50 is usually well tolerated by patients. However, pyramidal disorders, agitation, sleep disturbances, increased blood pressure, menstrual irregularities, impotence, galactorrhea and gynecomastia may occur.

Contraindications

Betamak T50 is contraindicated in cases of hypersensitivity to sulpiride, pheochromocytoma, hypertension, anxiety and psychomotor agitation. You should also avoid prescribing this drug to patients with renal failure, epilepsy, parkinsonism, the elderly and newborns. During pregnancy, Betamak T50 can only be used in low doses and not for a long time.

Interaction

Betamak T50 can enhance the effect of morphine derivatives, histamine H1 blockers, barbiturates, benzodiazepines and alcohol. Antihypertensive drugs increase the likelihood of developing orthostatic hypotension. Incompatible with levodopa (mutual antagonism). Antacids containing magnesium and aluminum hydroxide reduce bioavailability.

Overdose

Data on overdose of Betamak T50 with sulpiride are limited, but symptoms of extrapyramidal disorders, disturbances of consciousness, hypotension, cardiac arrhythmias, coma and even death may occur. Treatment consists of immediate hospitalization and measures to remove the drug from the body, maintaining vital functions and symptomatic therapy.

Conclusion

Betamak T50 is an effective drug for the treatment of schizophrenia, psychosis, gastric ulcer, migraine and other diseases. However, like any medication, it has side effects and contraindications, and can also interact with other medications. Therefore, the prescription and dose adjustment of Betamak T50 should be carried out only by a doctor.